Rebif

Ocrevus off to a flying start as Roche raises 2017 forecasts

The take-up of the drug has been buoyed by trials showing that the drug outperformed Merck KGaA's MS stalwart Rebif (interferon beta-1a) in two relapsing MS phase III

Roche sets disruptive price for new MS drug Ocrevus in US

Firm will significantly under cut rivals like Merck's Rebif. Roche has claimed US approval for its much anticipated new multiple sclerosis (MS) drug Ocrevus, and is pricing it at a ... market. It costs 20%-25% less than Rebif and other MS therapies

Avelumab costs peg back profit at Merck KGaA

Pfizer-partnered avelumab is central to Merck's plans to revitalise its healthcare business, currently under pressure as top-selling Rebif (interferon beta-1a) - an injectable treatment for multiple sclerosis - tries ... For now, Rebif is holding up

FDA delays verdict on Roche's MS drug Ocrevus

Ocrevus  is the first investigational medicine with the potential to treat both forms, outperforming Merck KGaA's Rebif (interferon beta-1a) in the two relapsing multiple sclerosis phase III trials and

Merck's pharma unit faces tougher 2017 as fertility boost recedes

2017". That's important because Gonal-f has buoyed Merck's healthcare unit in the face of declining sales for its two biggest products - injectable multiple sclerosis therapy Rebif (interferon

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]